{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T19:11:25Z","timestamp":1723403485955},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.thromres.2010.01.040","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T11:44:53Z","timestamp":1265888693000},"page":"S60-S62","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Long-term expression of canine FVIIa in hemophilic dogs"],"prefix":"10.1016","volume":"125","author":[{"given":"Paris","family":"Margaritis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2 Suppl 4","key":"10.1016\/j.thromres.2010.01.040_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminhematol.2006.03.002","article-title":"Inhibitor development in patients with hemophilia: an overview","volume":"43","author":"Leissinger","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1016\/j.thromres.2010.01.040_bib2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI20106","article-title":"Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII","volume":"7","author":"Margaritis","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2010.01.040_bib3","first-page":"440","article-title":"Species specificity of tissue thromboplastin","volume":"14","author":"Janson","year":"1984","journal-title":"Haemostasis"},{"key":"10.1016\/j.thromres.2010.01.040_bib4","first-page":"551","article-title":"Tissue factor activity of normal and neoplastic cells: quantitation and species specificity","volume":"70","author":"Kadish","year":"1983","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2010.01.040_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.thromres.2004.11.003","article-title":"Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study","volume":"116","author":"Petersen","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2010.01.040_bib6","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1172\/JCI32878","article-title":"Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality","volume":"118","author":"Aljamali","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2010.01.040_bib7","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2003-05-1498","article-title":"Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs","volume":"102","author":"Russell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-2002-32661","article-title":"Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII","volume":"28","author":"Brinkhous","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.thromres.2010.01.040_bib9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1073\/pnas.86.4.1382","article-title":"Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease","volume":"86","author":"Brinkhous","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2010.01.040_bib10","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1073\/pnas.82.24.8752","article-title":"Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs","volume":"82","author":"Brinkhous","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2010.01.040_bib11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jama.205.9.613","article-title":"A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors","volume":"205","author":"Brinkhous","year":"1968","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2010.01.040_bib12","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V88.7.2603.bloodjournal8872603","article-title":"Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B","volume":"88","author":"Brinkhous","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib14","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/hum.2006.17.427","article-title":"Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice","volume":"17","author":"Sarkar","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.thromres.2010.01.040_bib16","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood-2004-10-3867","article-title":"Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2\/8-mediated, liver-directed gene therapy","volume":"105","author":"Wang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib17","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1538-7836.2006.02203.x","article-title":"A novel missense mutation responsible for factor VII deficiency in research Beagle colonies","volume":"4","author":"Callan","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.040_bib18","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood-2008-07-168377","article-title":"Successful treatment of canine hemophilia by continuous expression of canine FVIIa","volume":"113","author":"Margaritis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib19","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.thromres.2010.01.040_bib21","doi-asserted-by":"crossref","first-page":"29195","DOI":"10.1074\/jbc.M102187200","article-title":"Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity","volume":"276","author":"Persson","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2010.01.040_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1042\/bj20031596","article-title":"Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement","volume":"379","author":"Persson","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.thromres.2010.01.040_bib23","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.1074\/jbc.M211629200","article-title":"Mutagenesis of the gamma-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site","volume":"278","author":"Harvey","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2010.01.040_bib24","doi-asserted-by":"crossref","first-page":"39825","DOI":"10.1074\/jbc.M104896200","article-title":"Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction","volume":"276","author":"Nelsestuen","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2010.01.040_bib25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1538-7836.2009.03287.x","article-title":"rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats","volume":"7","author":"Lauritzen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.040_bib26","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2003-05-1369","article-title":"Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A","volume":"102","author":"Tranholm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.040_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1538-7836.2008.03253.x","article-title":"Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects","volume":"7","author":"Moss","year":"2009","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810000939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810000939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T21:44:17Z","timestamp":1590615857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384810000939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":27,"alternative-id":["S0049384810000939"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2010.01.040","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}